Main Industry
Biotechnology
Main Product/Service
Sunhawk Vision Biotech, Inc. is the first RNA novel drug company in Taiwan, dedicated to developing innovative drugs (505(b)(1)) for the treatment of eye diseases. The eye drop currently under development, named SHJ002 eye drop, originates from the company's R&D team's world-first discovery that an excess of a type of RNA in the eyeball, known as microRNA (also referred to as "microRNA"), leads to disease. The R&D team has published a series of reports in internationally renowned journals (such as Investigative Ophthalmology & Visual Science (IOVS), Biomedicines, and Journal of Ocular Pharmacology and Therapeutics, among others), demonstrating that microRNA-328 can influence the expression of myopia-related genes through the mechanism of RNA interference. It is highly noteworthy that RNA interference (RNAi) and microRNA were the subjects of the Nobel Prize in Physiology or Medicine in 2006 and 2024, respectively.
Sunhawk Vision Biotech, Inc. is also one of the very few companies globally that have completed Phase 2 clinical trials for microRNA. In April 2024, Sunhawk Vision Biotech, Inc. announced the successful unblinding of its Phase 2 clinical trial for the treatment of dry eye disease, which not only significantly improved corneal staining but also achieved statistically significant results across multiple patient-reported symptoms. Currently, Sunhawk Vision Biotech, Inc. is conducting multiple clinical trials, including trials for childhood myopia control and prevention, as well as ocular surface-related diseases.
(The content above was translated by AI.)
Sunhawk Vision Biotech, Inc. is also one of the very few companies globally that have completed Phase 2 clinical trials for microRNA. In April 2024, Sunhawk Vision Biotech, Inc. announced the successful unblinding of its Phase 2 clinical trial for the treatment of dry eye disease, which not only significantly improved corneal staining but also achieved statistically significant results across multiple patient-reported symptoms. Currently, Sunhawk Vision Biotech, Inc. is conducting multiple clinical trials, including trials for childhood myopia control and prevention, as well as ocular surface-related diseases.
(The content above was translated by AI.)
Founded Year
2019
Unified Business No.
85009024
Status
Active
Number of Employees
0
Total Paid-in
Capital
703,421,590 (NT$)
Location of Company
Taiwan
, Kaohsiung City
Exit Status
Emerging Stock Exchange(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Sunhawk Vision Biotech, Inc. is a new drug development company focusing on first-in-class novel drugs. Its technology originates from a novel nucleic acid eye drop designed by the R&D team led by the founders of Sunhawk Vision Biotech, Inc., Professor Suh-Hang Juo and Dr. Jung-Ling Liang, which is an anti-myopia nucleic acid novel drug aimed at delaying the progression of myopia in children.
Through its exclusive patented microRNA technology, the R&D team has not only revealed the therapeutic potential of microRNA therapy in childhood myopia, but has also obtained safety data during the development process and completed relevant pharmacological and pharmacokinetic studies.
The establishment of Sunhawk Vision Biotech, Inc. originated from the guidance of the Biotech Integration and Innovation Center (Si2C) of the Ministry of Science and Technology and the Value Creation Program. With the assistance of the Ministry of Science and Technology, Sunhawk Vision Biotech, Inc. was established by the two founders in August 2019.
In addition to inheriting the missions and achievements of the two founders from academic research institutions, Sunhawk Vision Biotech, Inc.'s R&D team is dedicated to advancing early-stage research results into clinical trials. Furthermore, the R&D team continues to explore new indications for microRNA therapy, including clinical symptoms such as dry eye disease and corneal damage.
In January 2021, Sunhawk Vision Biotech, Inc. submitted an Investigational New Drug (IND) application for a Phase I clinical trial to the U.S. Food and Drug Administration (FDA) to evaluate the safety of the microRNA eye drops. The application was rapidly approved by the FDA in February of the same year. The trial (NCT04928144) was successfully completed in the third quarter of 2021, with no drug-related adverse events occurring during the trial, and the research results demonstrated that the drug was well-tolerated by pediatric subjects.
Subsequently, Sunhawk Vision Biotech, Inc. initiated a Phase II clinical trial (NCT05486728) for dry eye disease. This trial was completed and successfully unblinded in the second quarter of 2024, further proving the outstanding efficacy of the microRNA eye drops in improving dry eye symptoms. Currently, the research team continues to advance clinical trials for childhood myopia control and other corneal diseases. We sincerely hope that this innovative microRNA therapy will successfully pass all phases of clinical trials for various indications, thereby resolving the problems and difficulties of patients' unmet medical needs. At the same time, we look forward to promoting the drug globally in the coming years to benefit patients and improve human quality of life.
(The content above was translated by AI.)
Through its exclusive patented microRNA technology, the R&D team has not only revealed the therapeutic potential of microRNA therapy in childhood myopia, but has also obtained safety data during the development process and completed relevant pharmacological and pharmacokinetic studies.
The establishment of Sunhawk Vision Biotech, Inc. originated from the guidance of the Biotech Integration and Innovation Center (Si2C) of the Ministry of Science and Technology and the Value Creation Program. With the assistance of the Ministry of Science and Technology, Sunhawk Vision Biotech, Inc. was established by the two founders in August 2019.
In addition to inheriting the missions and achievements of the two founders from academic research institutions, Sunhawk Vision Biotech, Inc.'s R&D team is dedicated to advancing early-stage research results into clinical trials. Furthermore, the R&D team continues to explore new indications for microRNA therapy, including clinical symptoms such as dry eye disease and corneal damage.
In January 2021, Sunhawk Vision Biotech, Inc. submitted an Investigational New Drug (IND) application for a Phase I clinical trial to the U.S. Food and Drug Administration (FDA) to evaluate the safety of the microRNA eye drops. The application was rapidly approved by the FDA in February of the same year. The trial (NCT04928144) was successfully completed in the third quarter of 2021, with no drug-related adverse events occurring during the trial, and the research results demonstrated that the drug was well-tolerated by pediatric subjects.
Subsequently, Sunhawk Vision Biotech, Inc. initiated a Phase II clinical trial (NCT05486728) for dry eye disease. This trial was completed and successfully unblinded in the second quarter of 2024, further proving the outstanding efficacy of the microRNA eye drops in improving dry eye symptoms. Currently, the research team continues to advance clinical trials for childhood myopia control and other corneal diseases. We sincerely hope that this innovative microRNA therapy will successfully pass all phases of clinical trials for various indications, thereby resolving the problems and difficulties of patients' unmet medical needs. At the same time, we look forward to promoting the drug globally in the coming years to benefit patients and improve human quality of life.
(The content above was translated by AI.)
